Blueprint Medicines Corporation
BPMCNASDAQHealthcare
$129.46
+$0.18(+0.14%)
Market Cap$8.4B
P/E Ratio—
52W High$129.55
52W Low$73.04
Blueprint Medicines Corporation (BPMC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BPMC · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.51B | $0.25B | $0.20B | $0.18B | $0.79B |
| Cost of Revenue | $0.02B | $0.01B | $0.02B | $0.02B | $0.00B |
| Gross Profit | $0.49B | $0.24B | $0.19B | $0.16B | $0.79B |
| Gross Margin %(computed) | 96.04% | 94.87% | 91.27% | 90.04% | 99.95% |
| Operating Expenses | |||||
| R&D Expenses | $0.34B | $0.43B | $0.48B | $0.60B | $0.33B |
| G&A Expenses | $0.26B | $0.24B | $0.22B | $0.18B | $0.15B |
| Total Operating Expenses | $0.70B | $0.72B | $0.72B | $0.80B | $0.48B |
| Operating Income | ($0.21B) | ($0.49B) | ($0.55B) | ($0.65B) | $0.30B |
| Operating Margin %(computed) | -41.67% | -194.99% | -269.19% | -360.10% | 38.07% |
| Interest Income | $0.04B | $0.03B | $0.00B | $0.00B | $0.01B |
| Interest Expense | $0.07B | $0.05B | $0.02B | $0.00B | $0.00B |
| Income Before Tax | ($0.07B) | ($0.51B) | ($0.55B) | ($0.64B) | $0.31B |
| Income Tax Expense | $0.00B | $0.00B | $0.01B | $0.00B | $0.00B |
| Net Income | ($0.07B) | ($0.51B) | ($0.56B) | ($0.64B) | $0.31B |
| Net Margin %(computed) | -13.19% | -203.30% | -273.24% | -357.67% | 39.54% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.07 | $-8.37 | $-9.35 | $-11.01 | $5.76 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.05B |
| EBITDA | $0.02B | ($0.47B) | ($0.52B) | ($0.63B) | $0.31B |
| EBITDA Margin %(computed) | 3.78% | -188.61% | -252.61% | -348.90% | 38.89% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Blueprint Medicines Corporation data
About Blueprint Medicines Corporation (BPMC) Income Statement
Blueprint Medicines Corporation (BPMC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, BPMC reported revenue of $0.51B, gross profit of $0.49B (gross margin 96.04%), and net income of ($0.07B) — a net profit margin of -13.19%.
Frequently asked questions
BPMC · 4 questionsBlueprint Medicines Corporation (BPMC) reported revenue of $0.51B for 2024, up 104.0% year-over-year.
BPMC revenueBPMC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09